EGFR and non-small cell lung carcinoma: Recently, a crucial side effect has arisen as a lung-specific toxicity caused by an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer (NSCLC) [33].